Biophytis (BPTSY) AI Stock Analysis

• Market Cap: $3.31M
• Dividend Yield: N/A
• Average Volume (3M): 52.00
• Price to Earnings (P/E): ―
• Beta (1Y): 0.21
• Revenue Growth: N/A
• EPS Growth: 84.55%
• Country: US
• Employees: 22
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.96
• Shares Outstanding: 3,955,662
• 10 Day Avg. Volume: 88
• 30 Day Avg. Volume: 52
• PEG Ratio: 0.02
• Price to Book (P/B): -1.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.79
• Enterprise Value/Market Cap: 3.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -45.85
• Enterprise Value/Ebitda: -1.46
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.86
• Revenue Forecast (FY): $1.76M

• Rating: 35 Underperform
• Price Target: ―

Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.

Positive Factors

Proprietary Technology Platforms

The use of proprietary technology platforms provides Biophytis with a competitive edge in developing novel therapeutics, potentially leading to successful drug candidates and partnerships.

Pipeline Focus on Age-Related Diseases

Focusing on age-related diseases positions Biophytis to address a growing market need, potentially leading to significant long-term demand for its therapies.

Revenue Model Based on Partnerships

A revenue model based on partnerships and licensing agreements can provide a steady income stream and reduce financial risk by sharing development costs.

Negative Factors

Negative Equity

Negative equity indicates high leverage and financial instability, which can limit Biophytis' ability to raise capital and invest in R&D, impacting long-term growth.

Continuous Operating Losses

Ongoing operating losses reflect unprofitability and can strain financial resources, hindering Biophytis' ability to sustain operations and invest in future growth.

Reliance on External Financing

Dependence on external financing increases financial risk and may lead to unfavorable terms, impacting Biophytis' financial flexibility and long-term viability.

Biophytis Business Overview & Revenue Model

Company Description

Biophytis (BPTSY) is a clinical-stage biotechnology company focused on the development of therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases. The company's product pipeline includes drug candidates targeting neuromuscular diseases such as sarcopenia and other conditions like severe respiratory failure in COVID-19 patients. Biophytis utilizes its proprietary technology platforms to advance its research and development efforts in these areas.

How the Company Makes Money

Biophytis generates revenue through the development and potential commercialization of its drug candidates. The company's revenue model primarily focuses on licensing agreements, partnerships, and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Biophytis may receive funding from grants and research collaborations to support its clinical trials and research initiatives. The success of its revenue model is contingent upon the progression and approval of its drug candidates through clinical trials and regulatory processes.

Biophytis Financial Statement Overview

Summary

Biophytis is experiencing significant financial distress characterized by continuous operating losses, negative equity, and reliance on external financing. The absence of revenue poses a major challenge, while the ongoing cash burn and high debt levels present substantial risks to financial stability.

Income Statement

Biophytis has faced consistent financial challenges with no revenue generation over the past years. The company has significant negative EBIT and EBITDA margins due to high operating losses. Net profit margins remain deeply negative, reflecting the ongoing unprofitability.

Balance Sheet

The balance sheet reveals significant financial instability with negative stockholders' equity, indicating a concerning level of leverage. The debt-to-equity ratio cannot be calculated due to negative equity, and the company relies heavily on debt financing. Total liabilities exceed total assets, further highlighting financial vulnerability.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, indicating poor cash generation capabilities. However, a reduction in negative free cash flow over time suggests some improvements in cash management. The company is heavily reliant on financing activities for cash inflow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-226.08K	0.00	-803.00K	-484.00K	-311.00K	-280.00K
EBITDA	-7.08M	-8.26M	-13.80M	-22.79M	-26.50M	-13.66M
Net Income	-8.35M	-10.38M	-17.03M	-24.22M	-31.16M	-25.52M
Balance Sheet
Total Assets	7.77M	6.90M	11.96M	21.99M	36.26M	27.21M
Cash, Cash Equivalents and Short-Term Investments	1.42M	78.00K	5.93M	11.05M	25.16M	18.77M
Total Debt	9.12M	9.84M	8.27M	12.13M	16.65M	9.10M
Total Liabilities	16.95M	16.60M	15.85M	23.90M	30.56M	20.38M
Stockholders Equity	-9.14M	-9.67M	-3.86M	-1.88M	5.83M	2.30M
Cash Flow
Free Cash Flow	-2.68K	-8.64M	-13.09M	-19.13M	-24.14M	-10.08M
Operating Cash Flow	-4.04M	-8.64M	-12.87M	-18.99M	-23.80M	-9.86M
Investing Cash Flow	19.00	10.00K	370.00K	-17.00K	12.16M	-12.71M
Financing Cash Flow	5.27M	3.14M	7.03M	6.13M	29.71M	21.95M

Biophytis Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 1.6 is above the 20-day moving average (MA) of 0.91, above the 50-day MA of 1.11, and below the 200-day MA of 1.73, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 31.97 is Neutral, neither overbought nor oversold. The STOCH value of 11.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.

Biophytis Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	40 Underperform	$3.42M	-0.18	-82.17%	―	-3.27%	51.83%
BPTSY	35 Underperform	$3.31M	-0.10	―	―	―	84.55%
ONCO	33 Underperform	$2.22M	>-0.01	-263.57%	―	-34.58%	96.41%
OGEN	29 Underperform	$3.58M	-0.05	-168.95%	―	―	90.27%